Horizon Therapeutics plc
Horizon - Model ADX-914 -Fully Human Anti-IL-7Ra Antibody
Collaboration and option agreement with Q32 Bio to develop ADX-914, a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, two key immune pathways.
Most popular related searches
autoimmune disease
immune functional
clinical trial
dermatitis atopic
autoimmune
immune regulation
clinical phase
Atopic Dermatitis: Phase 2 trial being conducted by Q32 Bio to evaluate ADX-914 in atopic dermatitis.
Additional Autoimmune Disease: Phase 2 trial to be conducted by Q32 Bio to evaluate ADX-914 in a second autoimmune disease.
Horizon has an option to acquire ADX-914 from Q32 Bio on pre-negotiated terms through the completion of Phase 2 clinical trials.
